DK1456670T3 - Fremgangsmåde relateret til behandling af atherosklerose - Google Patents
Fremgangsmåde relateret til behandling af atheroskleroseInfo
- Publication number
- DK1456670T3 DK1456670T3 DK02758547T DK02758547T DK1456670T3 DK 1456670 T3 DK1456670 T3 DK 1456670T3 DK 02758547 T DK02758547 T DK 02758547T DK 02758547 T DK02758547 T DK 02758547T DK 1456670 T3 DK1456670 T3 DK 1456670T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- atherosclerosis
- procedure related
- atherosclerotic disorders
- lipid
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 238000013459 approach Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0120428A GB0120428D0 (en) | 2001-08-22 | 2001-08-22 | Method of analysis |
US32312701P | 2001-09-18 | 2001-09-18 | |
US35565502P | 2002-02-06 | 2002-02-06 | |
GB0202774A GB0202774D0 (en) | 2002-02-06 | 2002-02-06 | Methods and means |
GB0204611A GB0204611D0 (en) | 2002-02-27 | 2002-02-27 | Methods of measurement |
GB0216530A GB0216530D0 (en) | 2002-07-16 | 2002-07-16 | Methods and means |
GB0216755A GB0216755D0 (en) | 2002-07-18 | 2002-07-18 | Methods and means |
PCT/GB2002/003863 WO2003019198A2 (en) | 2001-08-22 | 2002-08-22 | Methods relating to treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1456670T3 true DK1456670T3 (da) | 2009-11-16 |
Family
ID=27562595
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02758547T DK1456670T3 (da) | 2001-08-22 | 2002-08-22 | Fremgangsmåde relateret til behandling af atherosklerose |
DK02755229T DK1454140T3 (da) | 2001-08-22 | 2002-08-22 | Diagnose og behandling af atherosklerose |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02755229T DK1454140T3 (da) | 2001-08-22 | 2002-08-22 | Diagnose og behandling af atherosklerose |
Country Status (9)
Country | Link |
---|---|
EP (3) | EP1454140B1 (da) |
JP (2) | JP4374248B2 (da) |
AT (1) | ATE436020T1 (da) |
AU (1) | AU2002321526A1 (da) |
DE (2) | DE60232913D1 (da) |
DK (2) | DK1456670T3 (da) |
EA (1) | EA009661B1 (da) |
ES (2) | ES2329770T3 (da) |
WO (3) | WO2003019198A2 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023368A1 (en) * | 2003-09-04 | 2005-03-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Prophylaxis of and treatment for infections from the family chlamydiaceae using amino acids as leucine or methionine |
WO2005027961A2 (en) * | 2003-09-23 | 2005-03-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Chlamydia pmpd autotransporter and its role as adhesin |
GB0323348D0 (en) * | 2003-10-06 | 2003-11-05 | Cambridge Theranostics Ltd | Methods and means for modulating lipid metabolism |
GB0503940D0 (en) * | 2005-02-25 | 2005-04-06 | Cambridge Theranostics Ltd | Assay methods |
GB0503939D0 (en) | 2005-02-25 | 2005-04-06 | Cambridge Theranostics Ltd | Chlamydia detection |
WO2006104402A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
GB0515035D0 (en) * | 2005-07-21 | 2005-08-31 | Cambridge Theranostics Ltd | Treatment of atherosclerotic conditions |
JP2009512426A (ja) * | 2005-10-14 | 2009-03-26 | イヴァン・ペテャエフ | 偏性細胞内病原体の治療および診断 |
ITRM20110233A1 (it) * | 2011-05-10 | 2012-11-11 | Univ Calabria | Azitromicina, suoi sali o solvati farmaceuticamente accettabili per l?uso come neuroprotettori. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1254311B (it) * | 1992-03-20 | 1995-09-14 | Sirc S P A Natural & Dietetic | Impiego di preparati contenenti cromo e vitamine e e c per il controllo del metabolismo glucidico e lipidico. |
EP0669132A1 (en) * | 1994-02-23 | 1995-08-30 | van der Kraaij, Antonius Marinus Maria | Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis |
DE69735591T2 (de) * | 1996-05-01 | 2007-04-05 | Avant Immunotherapeutics, Inc., Needham | Impfstoff auf einem plasmid beruhend zur behandlung von atherosclerosis |
ES2218833T3 (es) * | 1997-06-19 | 2004-11-16 | Lycored Natural Products Industries Ltd | Mezcla sinergetica de licopeno y vitamina e para la prevencion de la oxidacion de lipoproteinas de baja densidad (ldl). |
-
2002
- 2002-08-22 DE DE60232913T patent/DE60232913D1/de not_active Expired - Lifetime
- 2002-08-22 AU AU2002321526A patent/AU2002321526A1/en not_active Abandoned
- 2002-08-22 ES ES02758547T patent/ES2329770T3/es not_active Expired - Lifetime
- 2002-08-22 JP JP2003522512A patent/JP4374248B2/ja not_active Expired - Fee Related
- 2002-08-22 EP EP02755229A patent/EP1454140B1/en not_active Expired - Lifetime
- 2002-08-22 JP JP2003524011A patent/JP4307999B2/ja not_active Expired - Fee Related
- 2002-08-22 DK DK02758547T patent/DK1456670T3/da active
- 2002-08-22 DK DK02755229T patent/DK1454140T3/da active
- 2002-08-22 EP EP02755230A patent/EP1456402A2/en not_active Ceased
- 2002-08-22 AT AT02755229T patent/ATE436020T1/de not_active IP Right Cessation
- 2002-08-22 DE DE60232992T patent/DE60232992D1/de not_active Expired - Lifetime
- 2002-08-22 EP EP02758547A patent/EP1456670B8/en not_active Expired - Lifetime
- 2002-08-22 WO PCT/GB2002/003863 patent/WO2003019198A2/en not_active Application Discontinuation
- 2002-08-22 WO PCT/GB2002/003881 patent/WO2003019196A2/en active Application Filing
- 2002-08-22 WO PCT/GB2002/003884 patent/WO2003017992A2/en active Application Filing
- 2002-08-22 ES ES02755229T patent/ES2328907T3/es not_active Expired - Lifetime
- 2002-08-22 EA EA200400338A patent/EA009661B1/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2002321526A1 (en) | 2003-03-10 |
EP1454140A2 (en) | 2004-09-08 |
ES2328907T3 (es) | 2009-11-19 |
EP1456670A2 (en) | 2004-09-15 |
JP2005501258A (ja) | 2005-01-13 |
JP4307999B2 (ja) | 2009-08-05 |
EA200400338A1 (ru) | 2004-12-30 |
EP1456670B8 (en) | 2011-04-27 |
JP4374248B2 (ja) | 2009-12-02 |
WO2003019198A3 (en) | 2004-03-04 |
EP1456670B1 (en) | 2009-07-15 |
DK1454140T3 (da) | 2009-11-16 |
JP2005502665A (ja) | 2005-01-27 |
EA009661B1 (ru) | 2008-02-28 |
WO2003017992A2 (en) | 2003-03-06 |
DE60232992D1 (de) | 2009-08-27 |
ES2329770T3 (es) | 2009-12-01 |
WO2003019196A3 (en) | 2004-03-04 |
ATE436020T1 (de) | 2009-07-15 |
DE60232913D1 (de) | 2009-08-20 |
WO2003019198A2 (en) | 2003-03-06 |
WO2003019196A2 (en) | 2003-03-06 |
EP1456402A2 (en) | 2004-09-15 |
WO2003017992A3 (en) | 2004-06-17 |
EP1454140B1 (en) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE430742T1 (de) | Pyrimidinamine als angiogenesemodulatoren | |
DE60214461D1 (de) | Mantelgepumpter 3-Niveau Faserlaser/Verstärker | |
NO20032036L (no) | Kombinasjoner av medikamenter (f.eks. klorpromazin og pentamidiner) for behandling av neoplastiske forstyrrelser | |
NO20040097L (no) | Kombinasjoner for behandling av inflammatoriske forstyrrelser | |
ATE267830T1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen | |
NO20034056D0 (no) | Proliferative sykdommer | |
DK1404331T3 (da) | Sustained release-formuleringer af oxymorphon | |
DK1456670T3 (da) | Fremgangsmåde relateret til behandling af atherosklerose | |
NO20043085L (no) | Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet | |
DE60100737D1 (de) | Laserbehandlungsgerät | |
DK1648484T3 (da) | Fremgangsmåde til behandling af arthritis-tilstande | |
WO2002005848A3 (en) | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders | |
NO20023448D0 (no) | Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin | |
DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
NO20023737D0 (no) | Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse | |
DK1441723T3 (da) | Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension | |
NO20012423D0 (no) | Antikonvulsjonsmiddelderivater som er nyttige ved behandling av posttraumatiske stresslidelser | |
DK1385993T3 (da) | Fremgangsmåde til detektering og behandling af tuberøs sclerose kompleksrelaterede lidelser | |
NO20030137L (no) | Fremgangsmåte for behandling av ustabil angina pectoris | |
IS6619A (is) | S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum | |
SE0003126D0 (sv) | Method of treatment | |
ATE289510T1 (de) | Sulfonylpyridazinone derivate zur behandlung von ischämischem gewebeschaden | |
DK1500395T3 (da) | Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser | |
ITRM20000357A0 (it) | Processo per il trattamento di reflui di frantoi oleari. | |
DK1146866T3 (da) | Metode til behandling af patienter med akne ved administration af cyclisk GMP PDE inhibitator |